KINETIX is developing AI-guided, 3D-printed scaffold systems for sustained, site-specific drug release — beginning with glioblastoma.
Explore the platformInvestigational technology · Not approved for clinical use
Over 90% of GBM recurrences occur within 2 cm of the resection margin. Systemic chemotherapy fails to reach the site in therapeutic concentrations — the blood-brain barrier and tumor microenvironment see to that.
Scaffold geometry — pore size, spacing, connectivity — is computationally optimized to control drug release kinetics. This is not a shell; it is a tunable delivery system.
Pore diameter, wall thickness, and interconnectivity are treated as design variables. The lattice geometry itself sets how fast — and how far — the drug releases.
The scaffold is loaded with a drug-hydrogel formulation that fills and anchors within the pore structure. The hydrogel carrier provides sustained release kinetics while the scaffold maintains position in the resection cavity.
Drug diffuses outward from the scaffold in a controlled gradient, reaching the tumor margin without requiring systemic exposure. Release profiles are computationally predicted and experimentally validated.
The design tools, fabrication methods, and computational models KINETIX is building are generalizable. GBM is our proof of concept. The platform is designed for applications across the full spectrum of localized therapeutic delivery.
We're seeking research and development partnerships with pharmaceutical, biotech, and CRO organizations focused on localized drug delivery.
Get in touch